Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [896]

Accelerated partial breast irradiation not equivalent to whole breast...

Dr Frank Vicini - St Joseph Mercy Oakland, Pontiac, USA

Accelerated partial breast irradiation not equivalent to whole breast irradiation ( Dr Frank Vicini - St Joseph Mercy Oakland, Pontiac, USA )

Axillary radiotherapy and surgery show comparable long term outcomes for...

Prof Emiel Rutgers - Netherlands Cancer Institute Amsterdam, Netherlands

Axillary radiotherapy and surgery show comparable long term outcomes for patients with breast cancer ( Prof Emiel Rutgers - Netherlands Cancer Institute Amsterdam, Netherlands )

Gilteritinib combined with induction and consolidation chemotherapy in newly...

Dr Keith Pratz - Johns Hopkins University, Baltimore, USA

Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients ( Dr Keith Pratz - Johns Hopkins University, Baltimore, USA )

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for...

Dr Tait Shanafelt - Standford University, Stanford, USA

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL ( Dr Tait Shanafelt - Standford University, Stanford, USA )

NRAS mutant melanoma: Targeted therapy, are we there yet?

Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany

NRAS mutant melanoma: Targeted therapy, are we there yet? ( Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany )

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with...

Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve...

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC ( Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France )

Combination strategies of immunotherapy in breast cancer

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

Combination strategies of immunotherapy in breast cancer ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel...

Dr David R. Spigel - Tennessee Oncology, Nashville, USA

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...

Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Dr Susana Banerjee - The Institute of Cancer Research, London, UK

The standard of care and progress so far with PARP inhibitors for ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )

Cardiac events in stage III NSCLC treated in daily clinical practice

Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

Cardiac events in stage III NSCLC treated in daily clinical practice ( Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands )

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy

Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy ( Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer